Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Increasing trial participation for new cancer treatments

Posted on September 12th, 2022 by

Pharma R&D

Thanks to new and innovative treatments, cancer survival rates continue to improve dramatically – and this will likely only accelerate in the future. Each news cycle seems to carry a new flurry of good news – whether it’s ‘New cancer treatment offers hope to patients out of options’ or ‘How AI in precision medicine is helping find new treatments for brain tumors in children’.

(more…)

Ontologies – what do they have to do with pharma research?

Posted on August 24th, 2022 by

AI & Data

You would be forgiven for thinking that the topic of ontology is more the domain of philosophers or linguists – and not necessarily the concern of someone working in the life sciences. After all, the first definition you get if you Google the word ontology is “the branch of metaphysics dealing with the nature of being”. But dive deeper into the term, and you’ll discover that it’s about classifications of things and their relationships to each other – and that can most certainly be of interest to scientists.

(more…)

Fighting the stigmatization of monkeypox patients

Posted on August 11th, 2022 by

Pharma R&D

When disease outbreaks occur, health experts are not only faced with the challenge of getting good information out to people – they also must battle misinformation. Rumors fly, people share bits and pieces of articles that they only skimmed, and social media posts full of bad science go viral. Sometimes, when the outbreak begins in a certain locality or hits a particular demographic really hard, they must also contend with the problem of stigmatization – which is now happening with the monkeypox outbreak.

(more…)

Preprints offer early insights into research

Posted on August 9th, 2022 by

Pharma R&D

To stay competitive in R&D, it is critical to keep abreast of all the latest findings and innovations. Preprints are offering a new way to remain ahead of the curve, allowing a look into new research prior to the peer-review process.

(more…)

Mobilizing against monkeypox

Posted on August 3rd, 2022 by

Pharma R&D

As the world continues to navigate Covid and its many strains, it would be an understatement to say that everyone is on high alert for other types of outbreaks. Monkeypox is now top of mind, as the disease – first identified in humans in 1970 and mostly found in rainforest areas in Central and West Africa – is now seeing its largest-ever outbreaks outside of the African continent.

(more…)

Reaxys User Day 2022: Sharing insights and tips for streamlining the chemist workflow

Posted on June 14th, 2022 by

Chemistry

Whether you are an academic seeking a potential next-level cancer treatment, a pharma company charting out the competitive landscape, or a researcher wanting to stay on top of the latest bioactivity and pharmacological data relevant to your specialty, the Reaxys User Day 2022 proved a cornucopia of tips and tricks for chemists on how to streamline their workflow. Now, in case you missed the big day, these presentations are now online. Watch and learn.

(more…)

  1. 1
  2. 2
  3. 3
  4. 90

About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.